xrd-0394
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 24, 2021 (NCT05002140)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine-protein kinase ATMINHIBITOR
ATM inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06829173 | Early Phase 1 (Phase 1) | Apr 30, 2025 | New York University |
| NCT05002140 | Phase 1 | Aug 24, 2021 | XRad Therapeutics Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| New York University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| XRad Therapeutics Inc | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1